michele van vugt

  1. ME/CFS Skeptic

    Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation, 2025, Smeitink et al.

    Abstract Mitochondrial disease incorporates a group of rare conditions with no approved treatment to date, except for Leber hereditary optic neuropathy. Therapeutic options to alleviate the symptoms of mitochondrial disease are urgently needed. Sonlicromanol is a promising candidate, as it...
Back
Top Bottom